I focus on Precigen’s key attributes for now.
Only Item 6 on this old list needs to be deleted and cautiously optimistic it will be replaced with another attribute: efficacy.
Concurrently i keep an eye on ongoing AAV gene therapy launches
. Without repeat dosing to address durability they will have limited success. The GT treatment naive and AAV GT relapsers will be available for PGEN to address provided it has the appropriate funding to execute.
Setting a 2030 price target would be playing bingo. Just hibernate.